Docosahexaenoic Acid, Lutein and Zeaxanthin: study protocols
9 study groups took Docosahexaenoic Acid together with Lutein and Zeaxanthin. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Docosahexaenoic Acid
9 study groups in 8 studies say how much Docosahexaenoic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 78% of 9 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg or less | 1 |
| 100 mg to 250 mg | 1 |
| 250 mg to 500 mg | 7 |
Dose per serving from research: Lutein
9 study groups in 8 studies say how much Lutein participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 mg to 10 mg, 89% of 9 study groups.
| Daily dose | Study groups |
|---|---|
| 5 mg to 10 mg | 8 |
| 10 mg to 25 mg | 1 |
Dose per serving from research: Zeaxanthin
9 study groups in 8 studies say how much Zeaxanthin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 mg to 2.5 mg, 78% of 9 study groups.
| Daily dose | Study groups |
|---|---|
| 500 mcg to 1 mg | 2 |
| 1 mg to 2.5 mg | 7 |
Commonly used together
8 of 9 study groups took Docosahexaenoic Acid, Lutein and Zeaxanthin with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Omega-3 Fatty Acids | 7 |
9 study groups
| Study | |||||
|---|---|---|---|---|---|
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 350 mg | 10 mg | 2 mg | 5 years | — |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 300 mg | 10 mg | 2 mg | 12 weeks | 96 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 300 mg | 10 mg | 2 mg | 24 weeks | 40 |
| Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial 2022 · active group · Cognitively healthy adults aged 65 years and older | 430 mg | 10 mg | 2 mg | 2 years | 30 |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 350 mg | 10 mg | 2 mg | 5 years | — |
| Effects of lutein and docosahexaenoic Acid supplementation on macular pigment optical density in a randomized controlled trial 2013 · intervention group · Adults with early age-related macular degeneration; mean age 69.2 years, both sexes | 280 mg | 12 mg | 600 mcg | 1 year | 23 |
| Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial 2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified | 100 mg | 10 mg | 1 mg | 1 year | — |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 200 mg | 10 mg | 2 mg | — | 10 |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 350 mg | 10 mg | 2 mg | 5 years | — |